End-of-day quote
OTC Markets
03:30:00 01/09/2021 am IST
|
5-day change
|
1st Jan Change
|
2.63
CAD
|
-6.07%
|
|
+17.41%
|
+76.51%
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
205.5
|
177.2
|
102.4
|
364
|
-
|
-
|
Enterprise Value (EV)
1 |
141.4
|
123.5
|
85.8
|
193.6
|
238.2
|
186.1
|
P/E ratio
|
-4.1
x
|
-2.55
x
|
-2
x
|
-2.01
x
|
-3.46
x
|
-4.46
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
238
x
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
164
x
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-7.38
x
|
-2.71
x
|
-1.84
x
|
-2.87
x
|
-4.17
x
|
-2.74
x
|
EV / FCF
|
-7.38
x
|
-2.73
x
|
-1.8
x
|
-3.19
x
|
-4.16
x
|
-2.52
x
|
FCF Yield
|
-13.5%
|
-36.7%
|
-55.4%
|
-31.4%
|
-24%
|
-39.7%
|
Price to Book
|
1.52
x
|
2.24
x
|
2
x
|
0.82
x
|
1.98
x
|
1.64
x
|
Nbr of stocks (in thousands)
|
1,56,782
|
1,73,458
|
1,96,913
|
7,60,053
|
-
|
-
|
Reference price
2 |
1.310
|
1.021
|
0.5202
|
0.4762
|
0.4762
|
0.4762
|
Announcement Date
|
28/06/21
|
22/06/22
|
27/06/23
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.864
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-19.17
|
-45.64
|
-46.58
|
-67.35
|
-57.15
|
-67.95
|
EBIT
1 |
-
|
-32.28
|
-63.84
|
-51.52
|
-68.91
|
-67.88
|
-79.36
|
Operating Margin
|
-
|
-3,736.11%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-32.22
|
-67.63
|
-47.49
|
-74.69
|
-70.41
|
-77.47
|
Net income
1 |
-0.8098
|
-32.22
|
-67.63
|
-47.49
|
-74.54
|
-70.41
|
-84.23
|
Net margin
|
-
|
-3,729.17%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.3200
|
-0.4000
|
-0.2600
|
-0.2367
|
-0.1375
|
-0.1067
|
Free Cash Flow
1 |
-
|
-19.16
|
-45.31
|
-47.57
|
-60.75
|
-57.26
|
-73.84
|
FCF margin
|
-
|
-2,217.82%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/20
|
28/06/21
|
22/06/22
|
27/06/23
|
-
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-11.61
|
-11.95
|
-12.95
|
-11.19
|
-11.2
|
-11.04
|
-13.15
|
-12.64
|
-13.84
|
-26.88
|
-13.95
|
-13.8
|
-13.9
|
-14.2
|
-14.3
|
EBIT
1 |
-17.11
|
-16.46
|
-16.34
|
-13.4
|
-12.33
|
-12.09
|
-13.7
|
-12.71
|
-13.91
|
-27.02
|
-17.99
|
-14
|
-14.1
|
-14.4
|
-14.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.61
|
-17.21
|
-18.1
|
-13.06
|
-9.973
|
-10.74
|
-13.72
|
-14.51
|
-11.89
|
-30.33
|
-17.97
|
-12.5
|
-12.7
|
-13.1
|
-13.3
|
Net income
1 |
-17.61
|
-17.21
|
-18.1
|
-13.06
|
-10
|
-10.74
|
-13.72
|
-14.51
|
-11.89
|
-30.33
|
-18.35
|
-12.5
|
-12.7
|
-13.1
|
-13.3
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1100
|
-0.1000
|
-0.1000
|
-0.0700
|
-0.0600
|
-0.0600
|
-0.0700
|
-0.0700
|
-0.0500
|
-0.0900
|
-0.0417
|
-0.0100
|
-0.0100
|
-0.0200
|
-0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
10/02/22
|
22/06/22
|
08/08/22
|
14/11/22
|
14/02/23
|
27/06/23
|
14/08/23
|
14/11/23
|
14/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
64
|
53.6
|
16.6
|
170
|
126
|
178
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-19.2
|
-45.3
|
-47.6
|
-60.8
|
-57.3
|
-73.8
|
ROE (net income / shareholders' equity)
|
-
|
-73.6%
|
-79.2%
|
-76.4%
|
-46.4%
|
-22.4%
|
-26.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
0.8600
|
0.4600
|
0.2600
|
0.5800
|
0.2400
|
0.2900
|
Cash Flow per Share
2 |
-
|
-0.1900
|
-0.2700
|
-0.2600
|
-0.1400
|
-0.0500
|
-0.0500
|
Capex
1 |
-
|
0.14
|
0.11
|
0.14
|
0.04
|
3.01
|
5.89
|
Capex / Sales
|
-
|
15.62%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/11/20
|
28/06/21
|
22/06/22
|
27/06/23
|
-
|
-
|
-
|
Last Close Price
0.4762
CAD Average target price
6.089
CAD Spread / Average Target +1,178.75% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.42% | 11TCr | | +11.84% | 10TCr | | -14.15% | 2.24TCr | | -1.05% | 2.23TCr | | -5.29% | 1.91TCr | | -38.29% | 1.8TCr | | -4.16% | 1.79TCr | | +7.99% | 1.43TCr | | +36.24% | 1.25TCr |
Bio Therapeutic Drugs
|